Baseline Characteristics of Participants in the ASPREE (ASPirin in Reducing Events in the Elderly) Study
MetadataShow full item record
Background: There are no primary prevention trials of aspirin with relevant geriatric outcomes in elderly people. ASPirin in Reducing Events in the Elderly (ASPREE) is a placebo-controlled trial of low-dose aspirin that will determine whether 5 years of daily 100-mg enteric-coated aspirin extends disability-free and dementia-free life in a healthy elderly population and whether these benefits outweigh the risks. Methods: Set in primary care, this randomized double-blind placebo-controlled trial has a composite primary endpoint of death, incident dementia or persistent physical disability. Participants aged 70+ years (non-minorities) or 65+ years (U.S. minorities) were free of cardiovascular disease, dementia, or physical disability and without a contraindication to, or indication for, aspirin. Baseline data include physical and lifestyle, personal and family medical history, hemoglobin, fasting glucose, creatinine, lipid panel, urinary albumin:creatinine ratio, cognition (3MS, HVLT-R, COWAT, SDMT), mood (CES-D-10), physical function (gait speed, grip strength), Katz activities of daily living and quality of life (SF-12). Results: Recruitment ended in December 2014 with 16,703 Australian and 2,411 U.S. participants, a median age of 74 (range 65-98) years and 56% women. Approximately 55% of the U.S. cohort were from minority groups; 9% of the total cohort. Proportions with hypertension, overweight, and chronic kidney disease were similar to age-matched populations from both countries although lower percentages had diabetes, dyslipidemia, and osteoarthritis. Discussion: Findings from ASPREE will be generalizable to a healthier older population in both countries and will assess whether the broad benefits of daily low-dose aspirin in prolonging independent life outweigh the risks.
Showing items related by title, author, creator and subject.
Ryan, Joanne; Storey, Elsdon; Murray, Anne M; Woods, Robyn L; Wolfe, Rory; Reid, Christopher ; Nelson, Mark R; Chong, Trevor TJ; Williamson, Jeff D; Ward, Stephanie A; Lockery, Jessica E; Orchard, Suzanne G; Trevaks, Ruth; Kirpach, Brenda; Newman, Anne B; Ernst, Michael E; McNeil, John J; Shah, Raj C; ASPREE Investigator Group (2020)OBJECTIVE: To determine the effect of low-dose aspirin vs placebo on incident all-cause dementia, incident Alzheimer disease (AD), mild cognitive impairment (MCI), and cognitive decline in older individuals. METHODS: ...
McNeil, John J; Gibbs, Peter; Orchard, Suzanne G; Lockery, Jessica E; Bernstein, Wendy B; Cao, Yin; Ford, Leslie; Haydon, Andrew; Kirpach, Brenda; Macrae, Finlay; McLean, Catriona; Millar, Jeremy; Murray, Anne M; Nelson, Mark R; Polekhina, Galina; Reid, Christopher ; Richmond, Ellen; Rodríguez, Luz Maria; Shah, Raj C; Tie, Jeanne; Umar, Asad; van Londen, G.J.; Ronaldson, Kathlyn; Wolfe, Rory; Woods, Robyn L; Zalcberg, John; Chan, Andrew T; ASPREE Investigator Group (2020)BACKGROUND: ASPirin in Reducing Events in the Elderly (ASPREE), a randomized double-blind placebo-controlled trial (RCT) of daily low-dose aspirin (100 mg) in older adults, showed an increase in all-cause mortality, ...
Age-related macular degeneration in a randomized controlled trial of low-dose aspirin: Rationale and study design of the ASPREE-AMD studyRobman, L.; Guymer, R.; Woods, R.; Ward, S.; Wolfe, R.; Phung, J.; Hodgson, L.; Makeyeva, G.; Aung, K.; Gilbert, T.; Lockery, J.; Le-Pham, Y.; Orchard, S.; Storey, E.; Abhayaratna, W.; Reid, D.; Ernst, M.; Nelson, M.; Reid, Christopher; McNeil, J. (2017)Purpose: Although aspirin therapy is used widely in older adults for prevention of cardiovascular disease, its impact on the incidence, progression and severity of age-related macular degeneration (AMD) is uncertain. The ...